Can-Fite BioPharma Ltd. has made headlines with the announcement of promising results from its research on Piclidenoson, a drug aimed at treating kidney dysfunction related to Lowe syndrome. The findings indicate that this drug can improve kidney disease markers by up to 80% in preclinical studies. This breakthrough is significant not only for the company but also for the broader pharmaceutical industry, as it addresses a critical need for effective treatments in rare genetic disorders.

On November 12, 2026, Can-Fite issued a press release detailing the results of its study, which was published in the Nature Portfolio journal, Signal Transduction and Targeted Therapy. This research highlights the potential of Piclidenoson, an orally administered A3 adenosine receptor agonist, to correct cellular abnormalities associated with Lowe syndrome. The study was led by researchers at the Telethon Institute of Genetics and Medicine (TIGEM) and included collaborations from various international institutions.

Background

Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases. The company operates under the SIC code 2834, which pertains to pharmaceutical preparations. Its stock is traded on the NYSE under the ticker CANF. Recent filings indicate ongoing developments in its drug pipeline, including studies for other conditions such as psoriasis and liver cancer.

What the Filing Says

The recent filing states, "On November 12, 2026, Can-Fite BioPharma Ltd. issued a press release entitled 'Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal.'" This indicates the company is actively pursuing advancements in its research and development efforts.

Impact

The implications of this research are significant for patients suffering from Lowe syndrome, a rare genetic disorder that currently lacks curative therapies. The findings could also impact the pharmaceutical industry by demonstrating the effectiveness of targeted therapies for rare diseases. Additionally, the results may influence Can-Fite's standing among competitors in the pharmaceutical preparations sector, as they seek to address unmet medical needs.

What's Next

A Phase II clinical study has been designed and is currently under review by the Italian Health Authorities. This study aims to evaluate the efficacy and safety of Piclidenoson in adult patients with genetically confirmed Lowe syndrome.